StonvexLoading…
StonvexStonvexStonvexCore line items from CYTK's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $88.04M | $18.47M | $7.53M | $94.59M |
Operating Income | $-612.26M | $-536.25M | $-496.20M | $-324.20M |
Net Income | $-784.96M | $-589.53M | $-526.24M | $-388.95M |
EPS (Diluted) | $-6.54 | $-5.26 | $-5.45 | $-4.33 |
Total Assets | $1.42B | $1.40B | $824.32M | $1.01B |
Total Liabilities | $2.08B | $1.54B | $1.21B | $1.12B |
Cash & Equivalents | $122.52M | $94.86M | $113.02M | $65.58M |
Free Cash Flow OCF − CapEx | $-534.82M | $-399.80M | $-415.75M | $-310.85M |
Shares Outstanding | 122.94M | 118.21M | 101.64M | 94.83M |